These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 9194475

  • 1. Combination chemotherapy studies with gemcitabine.
    van Moorsel CJ, Veerman G, Bergman AM, Guechev A, Vermorken JB, Postmus PE, Peters GJ.
    Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-17-S7-23. PubMed ID: 9194475
    [Abstract] [Full Text] [Related]

  • 2. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
    van Moorsel CJ, Pinedo HM, Veerman G, Bergman AM, Kuiper CM, Vermorken JB, van der Vijgh WJ, Peters GJ.
    Br J Cancer; 1999 Jun; 80(7):981-90. PubMed ID: 10362105
    [Abstract] [Full Text] [Related]

  • 3. Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines.
    van Moorsel CJ, Pinedo HM, Veerman G, Guechev A, Smid K, Loves WJ, Vermorken JB, Postmus PE, Peters GJ.
    Biochem Pharmacol; 1999 Feb 15; 57(4):407-15. PubMed ID: 9933029
    [Abstract] [Full Text] [Related]

  • 4. Interaction between cisplatin and gemcitabine in vitro and in vivo.
    Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ.
    Semin Oncol; 1995 Aug 15; 22(4 Suppl 11):72-9. PubMed ID: 7481849
    [Abstract] [Full Text] [Related]

  • 5. Synergistic interaction between cisplatin and gemcitabine in vitro.
    Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ.
    Clin Cancer Res; 1996 Mar 15; 2(3):521-30. PubMed ID: 9816199
    [Abstract] [Full Text] [Related]

  • 6. In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model.
    Kanzawa F, Saijo N.
    Semin Oncol; 1997 Apr 15; 24(2 Suppl 7):S7-8-S7-16. PubMed ID: 9194474
    [Abstract] [Full Text] [Related]

  • 7. Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs.
    Bergman AM, Giaccone G, van Moorsel CJ, Mauritz R, Noordhuis P, Pinedo HM, Peters GJ.
    Eur J Cancer; 2000 Oct 15; 36(15):1974-83. PubMed ID: 11000580
    [Abstract] [Full Text] [Related]

  • 8. Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
    Ruiz van Haperen VW, Veerman G, Eriksson S, Stegmann AP, Peters GJ.
    Semin Oncol; 1995 Aug 15; 22(4 Suppl 11):35-41. PubMed ID: 7481843
    [Abstract] [Full Text] [Related]

  • 9. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
    Peters GJ, Van Moorsel CJ, Lakerveld B, Smid K, Noordhuis P, Comijn EC, Weaver D, Willey JC, Voorn D, Van der Vijgh WJ, Pinedo HM.
    Int J Oncol; 2006 Jan 15; 28(1):237-44. PubMed ID: 16328001
    [Abstract] [Full Text] [Related]

  • 10. Effect of gemcitabine and cis-platinum combinations on ribonucleotide and deoxyribonucleotide pools in ovarian cancer cell lines.
    Van Moorsel CJ, Smid K, Voorn DA, Bergman AM, Pinedo HM, Peters GJ.
    Int J Oncol; 2003 Jan 15; 22(1):201-7. PubMed ID: 12469205
    [Abstract] [Full Text] [Related]

  • 11. Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures.
    Padrón JM, van Moorsel CJ, Bergman AM, Smitskamp-Wilms E, van der Wilt CL, Peters GJ.
    Anticancer Drugs; 1999 Jun 15; 10(5):445-52. PubMed ID: 10477163
    [Abstract] [Full Text] [Related]

  • 12. Cytotoxic effects of gemcitabine-containing regimens against human non-small cell lung cancer cell lines which express different levels of p185neu.
    Tsai CM, Chang KT, Chen JY, Chen YM, Chen MH, Perng RP.
    Cancer Res; 1996 Feb 15; 56(4):794-801. PubMed ID: 8631016
    [Abstract] [Full Text] [Related]

  • 13. Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines.
    Kroep JR, Giaccone G, Tolis C, Voorn DA, Loves WJ, Groeningen CJ, Pinedo HM, Peters GJ.
    Br J Cancer; 2000 Oct 15; 83(8):1069-76. PubMed ID: 10993656
    [Abstract] [Full Text] [Related]

  • 14. Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.
    Hirsch FR, Helfrich B, Franklin WA, Varella-Garcia M, Chan DC, Bunn PA.
    Clin Breast Cancer; 2002 May 15; 3 Suppl 1():12-6. PubMed ID: 12057039
    [Abstract] [Full Text] [Related]

  • 15. Synergistic interaction between cisplatin and gemcitabine in ovarian and colon cancer cell lines.
    Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ.
    Adv Exp Med Biol; 1994 May 15; 370():139-43. PubMed ID: 7660877
    [No Abstract] [Full Text] [Related]

  • 16. Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780.
    Ruiz van Haperen VW, Veerman G, Eriksson S, Boven E, Stegmann AP, Hermsen M, Vermorken JB, Pinedo HM, Peters GJ.
    Cancer Res; 1994 Aug 01; 54(15):4138-43. PubMed ID: 8033147
    [Abstract] [Full Text] [Related]

  • 17. In vitro effects of combinations of cis-amminedichloro (2-methylpyridine) platinum (II) (ZD0473) with other novel anticancer drugs on the growth of SBC-3, a human small cell lung cancer cell line.
    Kanzawa F, Akiyama Y, Saijo N, Nishio K.
    Lung Cancer; 2003 Jun 01; 40(3):325-32. PubMed ID: 12781432
    [Abstract] [Full Text] [Related]

  • 18. [In vitro evaluation of potentially effective gemcitabine combination therapy for exocrine pancreatic carcinoma].
    Kreil A, Bauer J, Scheithauer W.
    Acta Med Austriaca; 1999 Jun 01; 26(3):93-100. PubMed ID: 10520377
    [Abstract] [Full Text] [Related]

  • 19. Mechanisms of synergism between gemcitabine and cisplatin.
    van Moorsel CJ, Veerman G, Vermorken JB, Voorn DA, Kroep JR, Bergman AM, Pinedo HM, Peters GJ.
    Adv Exp Med Biol; 1998 Jun 01; 431():581-5. PubMed ID: 9598132
    [No Abstract] [Full Text] [Related]

  • 20. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
    Bergman AM, Munch-Petersen B, Jensen PB, Sehested M, Veerman G, Voorn DA, Smid K, Pinedo HM, Peters GJ.
    Biochem Pharmacol; 2001 Jun 01; 61(11):1401-8. PubMed ID: 11331076
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.